We are one of Australia’s largest and most experienced Phase I clinical trials unit, with more than 23 years experience, an impressive global regulatory history and over 15,000 active volunteers on our database. Since our establishment in 1993, we have consistently maintained world class standards with a total commitment to providing excellence and quality in all areas of clinical trials, from volunteer and patient Phase I studies through to Phase II-IV clinical trials. Our 50-bed Phase I unit is ideally located within a brand new custom-built facility, adjacent to Adelaide’s new BioMed City and includes a 24-bed ambulatory cardiac telemetry monitoring system.
Our large database of volunteers allows for specific age, gender, ethnicity and other demographical requirements to be readily recruited, and our access to independent weekly HREC review meetings means fast study start-up times are routine.
CMAX helps you reach your clinical milestones faster.
By using the Australian Clinical Trial Notification (CTN) scheme we fast-track your product into the clinic without the need to file an IND, saving you 6-9 months of time and money.
Studies are initiated on a local human research ethics committee (HREC) approval, typically within just 5-6 weeks of submission.
CMAX has been FDA-audited, and studies are fully ICH GCP compliant and comply with the registration requirements of the US FDA, EMEA, Japanese and Canadian regulatory agencies.
CMAX has helped a number of our overseas clients register for the Australian R&D Tax Incentive scheme. This allows eligible companies to claim up to 43.5% cash rebate on qualifying R&D spend.
Therapeutic Areas: Pain / Anaesthesia, Dermatology, Metabolism / Endocrinology, Infectious Diseases, Vaccine, Monoclonal Antibody, Neurological, Oncology, Women’s Health, Allergy / Respiratory, Renal, Gastrointestinal, Cardiovascular, Rheumatology, Japanese, Haematology.